At a glance
ClinicalIndex Comparison RecordN/ACompleted· 48 enrolled
Drug / intervention
Dextromethorphan hydrobromidedrug
Likely dose
Dextromethorphan hydrobromide 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis
In Brief
A clinical study evaluating Dextromethorphan hydrobromide for Rheumatoid Arthritis. Completed, enrolled 48 participants.
Detailed Summary
Rheumatoid arthritis were randomized to a 6-month treatment of oral dextromethorphan hydrobromide or placebo as an add-on therapy to traditional disease-modifying anti-rheumatic drugs (DMARDs). Disease activity were assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
CollaboratorsTSH Biopharm Corporation Limited
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
Primary CompletionSep 2012
First PostedFeb 2015
TodayJul 2026
First PostedFeb 20, 2015
Enrollment StartJan 1, 2010
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.4 years ago
Interventions
Dextromethorphan hydrobromidedrug
120mg per day with once daily dose taken after breakfast for 6 months